MOD GRF 1-29 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
== History == Cloud laboratories were built on advancements made in laboratory automation in the 1990s. In the early 1990s, the modularity project of the Consortium of Automated Analytical Laboratory Systems worked to define standards by which biotechnology manufacturers could produce products that could be integrated into automated systems. In 1996, the National Committee for Clinical Laboratory Standards (now the Clinical and Laboratory Standards Institute) proposed laboratory automation standards that aimed to enable consumers of laboratory technology to purchase hardware and software from different vendors and connect them to each other seamlessly. The committee launched five subcommittees in 1997 and released standardization protocols to guide product development through the early 2000s. These early developments in interoperability led to early examples of lab automation using cloud infrastructure, such as the Robot Scientist "Adam" in 2009. This robot encapsulated and connected all the laboratory equipment necessary to perform microbial batch experiments. In 2010, D. J. Kleinbaum and Brian Frezza founded antiviral developer Emerald Therapeutics. To simplify laboratory testing, the group wrote centralized management software for their collection of scientific instruments and a database to store all metadata and results. In 2012, Transcriptic founded a robotic cloud laboratory for on-demand scientific research, which performed select tasks including DNA cloning remotely.
== Early life and entry to science == Hofmann was born in Germany but when his father died, his mother returned with her one-year-old son to her family home in Switzerland. The family was business oriented but Klaus was determined to pursue a career in science. He studied steroid chemistry at the Federal Institute of Technology in Zürich (ETH) in the laboratories of Leopold Ružička. Here he developed a friendship with another faculty member, Tadeus Reichstein from whom he learned laboratory technique. For his postdoctoral experience he traveled to the United States to work with Max Bergmann on peptides, an entirely new field for him. From there he migrated across the street to the laboratory of Vincent du Vigneaud where he was introduced to a new vitamin, Biotin.
== Epidemiology == Peyronie's disease is estimated to affect 1–20% of men. The condition becomes more common with age. The median age at onset of disease is 55–60 years although many cases have been recorded in adolescence and early 20's. The overall prevalence of Peyronie's disease is about 1–20% in men. Rates range from 3.2% in a community-based survey of 4,432 men (mean age of sample 57.4) to 16% among 488 men undergoing evaluation for erectile dysfunction (mean age 52.8). The prevalence of Peyronie's disease among the 4,432 men in the community based study who responded by self report positively for palpable plaque, newly occurring angulation or curvature and painful erection was 1.5% between the ages of 30 and 39, 3% between 40 and 49, 3% between 50 and 59, 4% between 60 and 69, and 6.5% over age 70. In 534 men undergoing routine prostate screening for cancer detection (without a specific urologic complaint), the prevalence of Peyronie's disease was 8.9%. In this study, the mean age of those with Peyronie's disease was 68.2 years compared with 61.8 years of those without Peyronie's disease. Accurately determining the prevalence of Peyronie's disease is difficult due to the embarrassment many patients feel about the condition. The actual prevalence is likely much higher than reported.
Ampicillin Amoxicillin There are many ampicillin precursors in existence. These are inactive compounds that are broken down in the gut to release ampicillin. None of these pro-drugs of ampicillin is in current use:
officer and member of the Fire Squad who can also transform into Premiere Deka Red and appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Rui Edogawa is portrayed by Leo Nagatsuma (長妻 怜央, Nagatsuma Reo). Ridomihan Mokumisu (リドミハ星人モクミス, Ridomiha Seijin Mokumisu): A botanical garden curator from Planet Ridomiha who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Mokumisu is voiced by Ayano Kawamura (川村 文乃, Kawamura Ayano), who also portrays her human form. Yoshiwan Raenjo (ヨシワ星人ラエンジョ, Yoshiwa Seijin Raenjo): Tarewarane's wife from Planet Yoshiwa who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Sometime prior to the special, she betrayed Tarewarane to the Space Police to flee his domestic violence. Raenjo is portrayed by Mei Kurokawa (黒川 芽以, Kurokawa Mei). Jiujissonian Rotmen (ジウジッソ星人ロットメン, Jiujisso Seijin Rottomen): Tarewarane's right-hand man from Planet Jiujisso who possesses the ability to assume an alien child form under the alias of Marple (マープル, Māpuru) and appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Following Tarewarane's deletion, Rotmen takes over his boss's plans and takes Rakamu hostage to use Raenjo as his pawn. However, his plans are eventually foiled by the Dekarangers and he is deleted by Ban / Premiere Deka Red. Rotmen is voiced by Jun Fukuyama (福山 潤, Fukuyama Jun).
Sources: en.wikipedia.org
Insect infestations, food shortages, and the destruction of provisions by rain and humidity presented ongoing challenges. Despite these hardships, Humboldt remained healthy and productive, documenting his scientific observations. Progressing up the Orinoco, the expedition reached Pararuma, where they met missionaries and Father Bernardo Zea, missionary of Atures and Maipures, who agreed to guide them further. Due to the rapids, a smaller canoe was acquired. The new canoe, hollowed from a single tree, was forty feet long and less than three feet wide. The arrangement left little space, resulting in cramped conditions for the passengers, supplies, and animal specimens. Native canoemen occupied the bow, and a mulatto servant from Cumana managed provisions and cooking. Insects continued to be a significant nuisance, and local methods of mitigation included sleeping in smoke-filled ovens, burying oneself in sand, or using mud and turtle oil as repellents. Humboldt also observed the use of rubber stoppers provided by local Natives. As the river narrowed, navigation through the Great Cataracts of Atures and Maipures required both paddling and hauling the canoe overland. Humboldt and Bonpland stayed at Father Zea’s mission during this process, where they observed a declining Native population, poor living conditions, and ongoing disease. Insect bites became a dominant hardship. Beyond the cataracts, the expedition entered little-documented territory.
Azinphos-methyl (Guthion) (also spelled azinophos-methyl) is a broad spectrum organophosphate insecticide manufactured by Bayer CropScience, Gowan Co., and Makhteshim Agan. Like other pesticides in this class, it owes its insecticidal properties (and human toxicity) to the fact that it is an acetylcholinesterase inhibitor (the same mechanism is responsible for the toxic effects of the V-series nerve agent chemical weapons). It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.
After the success of Raaz (2002), Morea appeared in a series of films throughout the mid-2000s. In 2003, he starred in three films: Baaz: A Bird in Danger, Chal: The Game of Death, and Sssshhh.... His role in Sssshhh... earned him a nomination for the Stardust Award for Superstar of Tomorrow – Male. In 2004, he appeared in four films. These included Ishq Hai Tumse, a remake of the Telugu film Sampangi; Plan, an action thriller directed by Sanjay Gupta; Insaaf: The Justice, in which he portrayed a police officer; and Rakt, a supernatural thriller. His performances in Plan and Rakt received a mixed critical response, with some reviewers noting his improvement in dramatic roles. In 2005, Morea appeared in Chehraa, playing a medical student opposite Bipasha Basu, Preeti Jhangiani, and Irrfan Khan. In 2006, he starred in Aksar, a commercially profitable thriller despite negative reviews. It is considered as his successful film after Raaz and Gunaah. He also appeared in Holiday, a musical romance directed by Pooja Bhatt. In 2007, he featured in Fight Club: Members Only, Tom, Dick, and Harry, and the Kannada-language remake Julie. He also played a supporting role in Aap Ki Khatir, which did not perform well at the box office. Morea had four releases in 2007. He starred in Life Mein Kabhie Kabhiee, which failed to perform commercially; made a cameo in Om Shanti Om during the song "Deewangi Deewangi"; appeared in Dus Kahaniyaan, an anthology film; and acted in Deha, his final release that year. In 2008, Morea acted in the thriller film Bhram, portraying a supermodel.
ATP hydrolysis by AAA ATPases is proposed to involve nucleophilic attack on the ATP gamma-phosphate by an activated water molecule, leading to movement of the N-terminal and C-terminal AAA subdomains relative to each other. This movement allows the exertion of mechanical force, amplified by other ATPase domains within the same oligomeric structure. The additional domains in the protein allow for regulation or direction of the force towards different goals.
Tranexamic acid is sometimes used in orthopedic surgery to reduce blood loss, to the extent of reducing or altogether abolishing the need for perioperative blood transfusion. It is of proven value in clearing the field of surgery and reducing blood loss when given before or after surgery. Drain and number of transfusions are reduced. In surgical corrections of craniosynostosis in children it reduces the need for blood transfusions. In spinal surgery (e.g., scoliosis), correction with posterior spinal fusion using instrumentation, to prevent excessive blood loss. In cardiac surgery, both with and without cardiopulmonary bypass (e.g., coronary artery bypass surgery), it is used to prevent excessive blood loss.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.